مجله جهانی جراحی پلاستیک
مجله جهانی جراحی پلاستیک
سه شنبه 25 اردیبهشت 1403
[Archive]
دوره 12، شماره 3 - ( 1402 )
جلد 12 شماره 3 صفحات 72-64 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nahaei M, Motazedian G, Mohammadi A, Davarpanah M A, Yazdanpanahi P, Ayareh , N, et al . Evaluation of Clinical Manifestations, Pattern of Involvement, and Surgical Outcomes in Patients with Post Covid-19 Head and Neck Mucormycosis Infection among Patients Admitted To Namazi Hospital, Shiraz, Iran (2021-2022). WJPS 2023; 12 (3) :64-72
URL: http://wjps.ir/article-1-1191-fa.html
URL: http://wjps.ir/article-1-1191-fa.html
Evaluation of Clinical Manifestations, Pattern of Involvement, and Surgical Outcomes in Patients with Post Covid-19 Head and Neck Mucormycosis Infection among Patients Admitted To Namazi Hospital, Shiraz, Iran (2021-2022). مجله جهانی جراحی پلاستیک. 1402; 12 (3) :64-72
چکیده: (1648 مشاهده)
Background: COVID-19, caused by SARS-CoV-2, is a global pandemic that particularly affects immunocompromised individuals, leading to secondary bacterial and fungal infections. Mucormycosis, caused by Mucorales fungi, is a severe infection primarily affecting immunocompromised individuals. The COVID-19 pandemic has seen a surge in mucormycosis cases worldwide, with India experiencing a significant increase. Various factors, including diabetes mellitus, contribute to the risk of mucormycosis. This study investigated head and neck mucormycosis in patients with prior COVID-19 infection.
Methods: Data from 45 patients were analyzed, with diabetes being the most common risk factor. Visual symptoms, ethmoid bone involvement, and orbital bone involvement were also identified as significant factors.
Results: The COVID-19 pandemic has led to an increase in mucormycosis cases, particularly in the head and neck region, with high mortality. Successful management involves addressing underlying factors, surgical debridement, and antifungal therapy.
Conclusion: Timely debridement reduces morbidity and mortality.
Methods: Data from 45 patients were analyzed, with diabetes being the most common risk factor. Visual symptoms, ethmoid bone involvement, and orbital bone involvement were also identified as significant factors.
Results: The COVID-19 pandemic has led to an increase in mucormycosis cases, particularly in the head and neck region, with high mortality. Successful management involves addressing underlying factors, surgical debridement, and antifungal therapy.
Conclusion: Timely debridement reduces morbidity and mortality.
فهرست منابع
1. 1 Cao H, Zhou Z, Wang L, et al. Screening of potential PFOS alternatives to decrease liver bioaccumulation: experimental and computational approaches. Environ Sci Technol 2019;53(5):2811-9. [DOI:10.1021/acs.est.8b05564]
2. 2 World Health Organization. Who director-general's opening remarks at the media briefing on COVID-19-11 march 2020. 2020 [cited 2023; Available from: https://www.who.int/director-general/speeches/detail/who-director-general-sopening-remarks-at-the-media-briefing-on-covid-19e-11-march-2020.
3. 3 Ripa M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect 2021;27(3):451-7. [DOI:10.1016/j.cmi.2020.10.021]
4. 4 Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020;185(4):599-606. [DOI:10.1007/s11046-020-00462-9]
5. 5 Prattes J, Wauters J, Giacobbe DR, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect 2022;28(4):580-7. [DOI:10.1016/j.cmi.2021.08.014]
6. 6 Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R, et al. Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis 2014;2014. [DOI:10.1155/2014/562610]
7. 7 Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18(3):556-69. [DOI:10.1128/CMR.18.3.556-569.2005]
8. 8 Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54(suppl_1):S23-S34. [DOI:10.1093/cid/cir866]
9. 9 Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. The Lancet Microbe 2022. [DOI:10.1016/S2666-5247(21)00237-8]
10. 10 Al Balushi A, Al Ajmi A, Al Sinani Q, et al. COVID-19-associated mucormycosis: an opportunistic fungal infection. A case series and review. Int J Infect Dis 2022;121:203-10. [DOI:10.1016/j.ijid.2022.05.005]
11. 11 Ghazi BK, Rackimuthu S, Wara UU, et al. Rampant increase in cases of mucormycosis in India and Pakistan: a serious cause for concern during the ongoing COVID-19 pandemic. The American Journal of Tropical Medicine and Hygiene 2021;105(5):1144. [DOI:10.4269/ajtmh.21-0608]
12. 12 Pasquier G. COVID-19-associated mucormycosis in India: why such an outbreak? Journal of Medical Mycology 2023:101393. [DOI:10.1016/j.mycmed.2023.101393]
13. 13 Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021;186:289-98. [DOI:10.1007/s11046-021-00528-2]
14. 14 Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020;12(9). [DOI:10.7759/cureus.10726]
15. 15 Venkatesh D, Dandagi S, Chandrappa PR, Hema K. Mucormycosis in immunocompetent patient resulting in extensive maxillary sequestration. Journal of oral and maxillofacial pathology: JOMFP 2018;22(Suppl 1):S112. [DOI:10.4103/jomfp.JOMFP_163_17]
16. 16 Sharma R, Kumar P, Rauf A, et al. Mucormycosis in the COVID-19 environment: a multifaceted complication. Frontiers in cellular and infection microbiology 2022;12:937481. [DOI:10.3389/fcimb.2022.937481]
17. 17 Arjmand P, Bahrami M, Mohammadie ZE, et al. Mucormycosis in pre‐COVID‐19 and COVID‐19 era: A study of prevalence, risk factors and clinical features. Laryngoscope Investigative Otolaryngology 2022;7(5):1343-50. [DOI:10.1002/lio2.899]
18. 18 Dogra S, Arora A, Aggarwal A, et al. Mucormycosis amid COVID-19 crisis: pathogenesis, diagnosis, and novel treatment strategies to combat the spread. Frontiers in microbiology 2022;12:794176. [DOI:10.3389/fmicb.2021.794176]
19. 19 Dam P, Cardoso MH, Mandal S, et al. Surge of mucormycosis during the COVID-19 pandemic. Travel Med Infect Dis 2023;52:102557. [DOI:10.1016/j.tmaid.2023.102557]
20. 20 Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2021;15(4):102146. [DOI:10.1016/j.dsx.2021.05.019]
21. 21 Talmi YP, Goldschmied-Reouven A, Bakon M, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngology-Head and Neck Surgery 2002;127(1):22-31. [DOI:10.1067/mhn.2002.126587]
22. 22 Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2022;32(4):NP11-NP6. [DOI:10.1177/11206721211009450]
23. 23 Vaughan C, Bartolo A, Vallabh N, Leong SC. A meta‐analysis of survival factors in rhino‐orbital‐cerebral mucormycosis-has anything changed in the past 20 years? Clin Otolaryngol 2018;43(6):1454-64. [DOI:10.1111/coa.13175]
24. 24 Sahoo NK, Kulkarni V, Bhandari AK, Kumar A. Mucormycosis of the frontal sinus: A rare case report and review. Annals of Maxillofacial Surgery 2017;7(1):120.
25. 25 Maliwan N, Reyes CV, Kippon JW. Osteomyelitis secondary to cutaneous mucormycosis: report of a case and a review of the literature. The American journal of dermatopathology 1984;6(5):479-82. [DOI:10.1097/00000372-198410000-00011]
26. 26 Prabhakar A, Prabhakar N, Garg M, Kumar A. The Integral Role of Radiology in the Diagnosis and Management of COVID-19-Associated Mucormycosis Infections. The American Journal of Tropical Medicine and Hygiene 2022;106(4):1022. [DOI:10.4269/ajtmh.21-1135]
27. 27 Agrawal A, Dixit Y, Yonati V, Nigam P, Kheti P. Imaging of COVID-19-associated rhino-orbital-cerebral mucormycosis: imaging analysis of 120 patients. The Egyptian Journal of Otolaryngology 2022;38(1):1-8. [DOI:10.1186/s43163-022-00342-7]
28. 28 Joshi AR, Muthe MM, Patankar SH, Athawale A, Achhapalia Y. CT and MRI findings of invasive mucormycosis in the setting of COVID-19: experience from a single center in India. American Journal of Roentgenology 2021;217(6):1431-2. [DOI:10.2214/AJR.21.26205]
29. 29 Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018;56(suppl_1):S93-S101. [DOI:10.1093/mmy/myx101]
30. 30 Amanati A, Zekavat OR, Foroutan H, et al. Case reports of invasive mucormycosis associated neutropenic enterocolitis in leukemic children: diagnostic and treatment challenges and review of literature. BMC Infect Dis 2021;21:1-9. [DOI:10.1186/s12879-021-06957-0]
31. 31 Sharma A, Goel A. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol (Praha) 2022;67(3):363-87. [DOI:10.1007/s12223-021-00934-5]
32. 32 Arbune M, Arbune A-A, Nechifor A, Chiscop I, Sapira V. Diagnostic and Treatment Challenges of Emergent COVID-Associated-Mucormycosis: A Case Report and Review of the Literature. Antibiotics 2022;12(1):31. [DOI:10.3390/antibiotics12010031]
33. 33 Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. Journal of Fungi 2019;5(1):26. [DOI:10.3390/jof5010026]
34. 34 Kara I, Tasova Y, Uguz A, Sahin B. Mucormycosis‐associated fungal infections in patients with haematologic malignancies. Int J Clin Pract 2009;63(1):134-9. [DOI:10.1111/j.1742-1241.2006.01145.x]
35. 35 Mirza H, Noori MAM, Akbar H, et al. Hypertension as an independent risk factor for in-patient mortality in hospitalized COVID-19 patients: a multicenter study. Cureus 2022;14(7). [DOI:10.7759/cureus.26741]
36. 36 Huang S, Wang J, Liu F, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 2020;43(8):824-31. [DOI:10.1038/s41440-020-0485-2]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
